6 semaglutide PIONEER 6: Oral Passes Test in Cardiovascular Outcomes Study Oral Semaglutide and Cardiovascular Outcomes

(2022) identified the Mg-Na-SO 4 dominant brines of the Basque Lakes, which lie within the Thomspon Plateau in British Columbia, Canada, as a plausible geochemical analogue for the ice shell-ocean interface and sub-ice environment of Europa

No therapeutic or diagnostic claims are made

van Geijlswijk, I

For context on how these results compare with single-agonist options, semaglutide (Wegovy) achieved 14.9% mean weight loss at 68 weeks in the STEP 1 trial, and retatrutide , a triple agonist targeting GLP-1, GIP, and glucagon receptors, showed up to 24.2% weight loss in Phase 2

suis culture in both Minimal Essential medium (MEM) and Mueller Hinton (MH) medium (Fig

So this is not a takedown piece